The emergence of SARS-CoV-2 variants necessitates rational assessment of their impact on
the recognition and neutralization of the virus by the host cell. We present a comparative …

The profound understanding and detailed evaluation of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) spike (SCoV2-S) protein and specific antibody interaction …

Background As vaccines against SARS-CoV-2 are now being rolled out, a better
understanding of immunity to the virus, whether from infection, or passive or active …

Antibodies to SARS-CoV-2 are central to recovery and immunity from COVID-19. However,
the relationship between disease severity and the repertoire of antibodies against specific …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of
the outbreak led to the coronavirus disease 2019 (COVID-19) pandemic. Receptor binding …

A novel phenoxy-bridged trinuclear nickel (II) complex [Ni3 (μ-L) 2 (bipy) 3](1)(where
H3L=(E)-2-hydroxy-N-(2-hydroxy-3, 5-diiodophenyl)-3, 5-diiodobenzohydrazonic acid, bipy …

SARS-CoV-2 strains have made an appearance across the globe, causing over 757 million
cases and over 6.85 million deaths at the time of writing. The emergence of these variants …

The constantly mutating severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
poses great risk of efficacy loss to the present neutralizing therapeutics. Thus, it is urgently …

Neutralizing antibodies (NAbs) are elicited after infection and vaccination and have been
well studied. However, their antibody‐dependent cellular cytotoxicity (ADCC) functionality is …

Background The infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) has unpredictable manifestations of coronavirus disease (COVID-19) and variable clinical …